Lipid soluble steroid prodrugs

Details Lipid soluble steroid prodrugs Lipid soluble steroid prodrugs

2000-02-03

2002-09-03

Badio, Barbara P. (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

Reexamination Certificate

active

06444660

ABSTRACT:

FIELD OF THE INVENTION
The present invention is directed, inter alia, to novel lipid soluble steroid prodrugs, and to uses for the same.
BACKGROUND OF THE INVENTION
Prodrugs comprise inactive forms of active drugs where a chemical group is present on the prodrug which renders it inactive and/or confers solubility or some other property to the drug. Prodrugs are generally inactive, but once the chemical group has been cleaved from the prodrug, by heat, cavitation, pressure, and/or enzymes in the surrounding environment, the active drug is generated. Prodrugs may be designed as reversible drug derivatives and utilized as modifiers to enhance drug transport to site-specific tissues. Prodrugs are described in the art, for example, in Sinkula et al.,
J. Pharm. Sci
., (1975) 64:181-210, the disclosure of which is hereby incorporated herein by reference in its entirety.
Steroids encompass a variety of compounds having the general cyclopentanoperhydrophenanthrene ring system set forth below.
Steroids cause a variety of therapeutic effects, including enhanced anabolism, e.g., aldosterone, and anti-inflammatory effects, e.g., corticosteroids. Steroids such as cortisone and dexamethasone are potent immune suppressants and are used to treat conditions such as autoimmune diseases, organ transplant rejection, arthritis, skin, mucosal membrane and ophthalmic inflammation, as well as neoplastic conditions such as lymphoma. There are a variety of deleterious side effects associated with prolonged or high doses of steroids, such as fatigue, muscle wasting, bone loss resulting in pathologic fractures, salt and fluid retention, hypertension and heart disease, immunosuppression and infection, and avascular necrosis of the weight bearing articular surfaces of bones, such as the hips.
It is often difficult to deliver appropriate concentrations of steroids to target tissues. For example, in ophthalmic therapy, eye drops may be employed to deliver steroid hormones to the eye. However, the duration of action is short, and less than 3% of the steroid typically penetrates the cornea. As a partial solution to this problem, intraocular injections have been employed to increase the dosage.
The design of steroid prodrugs to date has been to increase the effective water solubility of the steroid. For example, Fedorak, et al.,
Am. J. Physiol
, 269: G210-218 (1995), describe dexamethasone-&bgr;-D-glucuronide; McLoed, et al.,
Gastroenterol
., 106:405-413 (1994), describe dexamethasone-succinate-dextrans; and Hochhaus, et al,
Biomed Chrom
., 6:283-286 (1992), describe dexamethasone-21-sulphobenzoate sodium and dexamethasone-21-isonicotinate.
A new way of delivering higher concentrations of steroids to the target tissue is needed to improve the efficacy of steroids as well as to lessen the side-effects associated with steroid use. The present invention is directed to these, as well as other, ends.
SUMMARY OF THE INVENTION
The present invention is directed to a compound comprising a steroid covalently bonded to a lipid moiety via a linking group.
In another embodiment, the compound comprising a steroid covalently bonded to a lipid moiety via a linking group may be of formula (I):
D—X—L  (I)
wherein:
D is a steroid;
X is a linking group comprising an ester group, a carbamate group, a carbonyl group, a thioester group, a disulfide group, an ether group, an anhydride group, or an amide group; and
L is a lipid moiety comprising an acyl, alkyl, alkylaryl, fluoroacyl, fluoroalkyl or fluoroalkylaryl group having from about 4 to about 40 carbon atoms.
In another embodiment, the compound comprising a steroid covalently bonded to a lipid moiety via a linking group may be a compound of the formula (II), which is within the scope of formula (I):
wherein:
each X
1
is independently a direct bond, —O—, —S—, —SO—, —SO
2
—, —NR
4
—, —X
3
—C(═X
4
)—, —C(═X
4
)—X
3
— or —C(═X
4
)—;
X
2
is a direct bond, —C(═X
4
)—, —R
5
—X
3
—C(═X
4
)—, —R
5
—C(═X
4
)—X
3
, —X
3
—C(═X
4
)—R
5
—, —C(═X
4
)—X
3
—R
5
—, —X
3
—R
5
—C(═X
4
)—X
3
—, —C(═X
4
)—R
5
—C(═X
4
)—, —C(═X
4
)—R
5
—C(═X
4
)—X
3
—, —R
5
—X
3
—C(═X
4
)—R
5
—C(═X
4
)—X
3
—, or —R
5
—C(═X
4
)—X
3
—R
5
—C(═X
4
)—;
each X
3
is independently —O—, —NR
4
— or —S—;
each X
4
is independently O or S;
M is —R
5
—X
3
—, —R
5
—X
3
—C(═X
4
)—, —R
5
—C(═X
4
)—X
3
—, —R
5
—X
3
—(YX
4
)P(═X
4
)—X
3
— or —X
3
—(YX
4
)P(═X
4
)—X
3
—R
5
—;
Y is a hydrogen atom or a pharmaceutically acceptable counter ion;
D is a steroid;
each n is independently an integer of 0 or 1;
each R
1
is independently an alkyl group of 1 to about 50 carbon atoms that is optionally substituted with one or more halogen atoms;
each R
2
is independently an alkylene group of 1 to about 30 carbon atoms that is optionally substituted with one or more halogen atoms;
each of R
3
and R
4
is independently ═O, a hydrogen atom or an alkyl group of 1 to about 10 carbon atoms; and
each R
5
is independently a direct bond or an alkylene group of 1 to about 30 carbon atoms.
Another embodiment of the invention is directed to a composition comprising, in an aqueous carrier, a steroid covalently bonded to a lipid moiety via a linking group.
Another embodiment of the invention provides a method of delivering a steroid to a patient comprising administering to the patient a composition comprising a steroid covalently bonded to a lipid moiety via a linking group. If desired, the method may further comprise the step of imaging the patient with diagnostic ultrasound to monitor the location of the composition in the patient. Also, if desired, the method may comprise the step of applying therapeutic ultrasound to the patient to facilitate localization of the steroid in a desired region of the patient.
The steroid covalently bonded to the lipid moiety via the linking group may be, for example, a compound of formula (I) or formula (II) above. The lipid moiety that is covalently bonded to the steroid via a linking group may form a vesicle or may be non-vesicular, as desired. The compositions of the invention may also comprise a wide variety of components, including, for example, one or more of gases, gaseous precursors, liquids, stabilizing materials, targeting ligands and other bioactive agents. The stabilizing materials may comprise, for example, lipids, proteins, polymers, surfactants, and the like. The stabilizing materials may be in the form of a vesicle or may be non-vesicular, forming, for example, an emulsion, suspension, dispersion or the like.


REFERENCES:
patent: 3015128 (1962-01-01), Sommerville et al.
patent: 3291843 (1966-12-01), Fritz et al.
patent: 3293114 (1966-12-01), Kenaga et al.
patent: 3401475 (1968-09-01), Morehouse et al.
patent: 3479811 (1969-11-01), Walters
patent: 3488714 (1970-01-01), Walters et al.
patent: 3532500 (1970-10-01), Priest et al.
patent: 3557294 (1971-01-01), Dear et al.
patent: 3594326 (1971-07-01), Himmel et al.
patent: 3615972 (1971-10-01), Morehouse et al.
patent: 3647784 (1972-03-01), Stein et al.
patent: 3649620 (1972-03-01), Ercoli et al.
patent: 3650831 (1972-03-01), Jungermann et al.
patent: 3732172 (1973-05-01), Herbig et al.
patent: 3873564 (1975-03-01), Schneider et al.
patent: 3945956 (1976-03-01), Garner
patent: 3960583 (1976-06-01), Netting et al.
patent: 3968203 (1976-07-01), Spitzer et al.
patent: 4027007 (1977-05-01), Messina
patent: 4089801 (1978-05-01), Schneider
patent: 4108806 (1978-08-01), Cohrs et al.
patent: 4138383 (1979-02-01), Rembaum et al.
patent: 4162282 (1979-07-01), Fulwyler et al.
patent: 4179546 (1979-12-01), Garner et al.
patent: 4192859 (1980-03-01), Mackaness et al.
patent: 4224179 (1980-09-01), Schneider
patent: 4229360 (1980-10-01), Schneider et al.
patent: 4265251 (1981-05-01), Tickner
patent: 4276885 (1981-07-01), Tickner et al.
patent: 4310505 (1982-01-01), Baldeschwieler et al.
patent: 4310506 (1982-01-01), Baldeschwieler et al.
patent: 4315514 (1982-02-01), Drewes et al.
patent: 4331654 (1982-05-01), Morris
patent: 4342826 (1982-08-01), Cole

Affiliated with

Also associated with

Rating

Lipid soluble steroid prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lipid soluble steroid prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid soluble steroid prodrugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2838755